万赛维治什么呢？

It is suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis and the prevention of CMV infection in high-risk solid organ transplant patients. Human viruses to which Vancevir is sensitive include human cytomegalovirus (HCMV), Vancevir is sensitive to herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV) and hepatitis B virus.

Vancevir can inhibit viral activity mainly by inhibiting the synthesis of viral DNA: Vancevir competitively inhibits viral DNA polymerase, preventing deoxyguanosine triphosphate from binding to DNA. Vancevir's ganciclovir triphosphate binds to viral DNA, terminating or limiting the elongation of the viral DNA chain. The IC50 of the antiviral effect of ganciclovir on CMV in vitro ranges from 0.08μM (0.02ug/ml) to 14μM (3.5ug/ml).

Adult patients: (1) Induction treatment of CMV retinitis: For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity. (2) Maintenance treatment of CMV retinitis: After induction therapy, or for patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis. (3) Prevention of CMV infection in transplant patients: ① For kidney transplant patients, the recommended dose is 900 mg (two 450 mg tablets), once a day, starting within 10 days after transplantation until 200 days after transplantation. ②For patients who have received a solid organ transplant other than kidney, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.